Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma

Katô, Kôji; Miyamoto, Toshihiro; Numata, Akihiko; Nakaike, Takashi; Oka, Hiromi; Yurino, Ayano; Kuriyama, Takuro; Mori, Yasuo; Yamasaki, Satoshi; Muta, Tsuyoshi; Takenaka, Katsuto; Iwasaki, Hiromi; Teshima, Takanori; Akashi, Koichi

doi:10.1007/s12185-013-1278-z

Cited by 12 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A post-marketing survey showed that the incidence of severe dermatological complications such as SJS and TEN was approximately 1 % in patients treated with mogamulizumab, and other complications including diffuse panbronchitis and the reactivation of hepatitis B virus have been also reported [10,11]. These unique events are considered to be immune-related triggered by the depletion of Treg.…”

Section: Discussionmentioning

confidence: 99%

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab

et al. 2015

View full text Add to dashboard Cite

A 57-year-old male with acute-type adult T cell leukemia-lymphoma (ATL) developed persistent watery, non-bloody diarrhea at a volume of 2-3 L/day following the administration of the anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, mogamulizumab. An extensive examination revealed the absence of any pathogenic bacteria or parasites in his stool. Biopsied specimens from the colonic mucosa contained many small nests of apoptotic bodies in the colonic glands, which mimicked acute-colonic graft-versus-host disease. Activation of the auto-reactive immune system due to the depletion of regulatory T-cells by mogamulizumab was suspected as causative. Special attention should be paid to the risk of unique immune-related adverse events induced by mogamulizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab

et al. 2015

View full text Add to dashboard Cite

show abstract

“…ATLL usually resists conventional chemotherapy and must be treated soon after diagnosis because of the rapid proliferation of tumor cells, which generates a high tumor burden [2,3]. In the future, novel agents, such as mogamulizumab, a humanized anti-CCR4 monoclonal antibody, might improve CBT-associated survival by decreasing the tumor burden before transplantation [32][33][34][35]. Another possibility for improving survival might be reducing the time from diagnosis to transplantation while patients with ATLL remain chemosensitive.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey

Katô

Choi

Wake

et al. 2014

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Allogeneic bone marrow and peripheral blood stem cell transplantations are curative treatment modalities for adult T cell leukemia/lymphoma (ATLL) because of the intrinsic graft-versus-ATLL effect. However, limited information is available regarding whether cord blood transplantation (CBT) induces a curative graft-versus-ATLL effect against aggressive ATLL. To evaluate the effect of CBT against ATLL, we retrospectively analyzed data from 175 patients with ATLL who initially underwent single-unit CBT. The 2-year overall survival (OS) rate was 20.6% (95% confidence interval [CI], 13.8% to 27.4%). A multivariate analysis revealed that the development of graft-versus-host disease (GVHD) was a favorable prognostic factor for OS (hazard ratio, .10; 95% CI, .01 to .94; P = .044). Furthermore, the 2-year OS (42.7%; 95% CI, 28.1% to 56.6%) of patients with grade 1 to 2 acute GVHD was higher than that of patients without acute GVHD (24.2%; 95% CI, 11.2% to 39.8%; P = .048). However, the cumulative incidence of treatment-related mortality (TRM) was high (46.1%; 95% CI, 38.2% to 53.7%), and early death was particularly problematic. In conclusion, CBT cures patients with ATLL partly through a graft-versus-ATLL effect. However, novel interventions will be required, particularly in the early phase, to reduce TRM and optimize GVHD.

show abstract

“…40 In this case, the number of CD4+CD25+FOXP3+ cells was low, and CD8+ cells had increased just before the onset of diffuse panbronchiolitis. CD8+ cells and neutrophils, together with inflammatory cytokines, are believed to play key roles in the development of diffuse panbronchiolitis.…”

Section: Diffuse Panbronchiolitismentioning

confidence: 69%

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma

Yoshimitsu¹,

Arima²

2014

BLCTT

View full text Add to dashboard Cite

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by latent infection of human T-cell lymphotropic virus type 1. The outcome for ATLL is very poor, with a 3-year overall survival of approximately 24% with conventional chemotherapy; thus, there is an unmet need for developing new treatment options. Defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody (KW-0761, mogamulizumab) has been clinically available for the treatment of relapsed or refractory ATLL in Japan since 2012, and a Phase II study of mogamulizumab for patients with relapsed CCR4+ ATLL demonstrated a 50% objective response, a 30.8% complete response, and an acceptable safety profile. Allogeneic hematopoietic stem cell transplantation has been used to treat patients with ATLL, and mogamulizumab in combination with allogeneic hematopoietic stem cell transplantation has been used successfully in a limited number of patients to treat refractory or relapsed ATLL. The efficacy of combining mogamulizumab with standard chemotherapy (mLSG15) for patients with ATLL has also been examined, and the results have shown higher rates of complete response with the combined therapy (52%) compared with for chemotherapy alone (33%). Mogamulizumab also has potential application in the treatment of human T-cell lymphotropic virus type 1-associated myelopathy/tropical paraparesis, Epstein-Barr virus-associated T-cell and natural killer-cell lymphoproliferative diseases, and peripheral and cutaneous T-cell lymphomas. Possible adverse events of mogamulizumab have been reported, such as cutaneous adverse reactions (including Stevens-Johnson syndrome), diffuse panbronchiolitis, reactivation of hepatitis B, and opportunistic infections. The treatment outcome of patients with ATLL might be improved by further optimizing the use of mogamulizumab and managing severe adverse events. In this review, we provide an overview of the current treatment options for patients with ATLL and a focused review on the use, application, and adverse events associated with mogamulizumab.

show abstract

Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma

Cited by 12 publications

References 16 publications

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab

Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey

Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma

Contact Info

Product

Resources

About